Comments
Strides Pharma Science Limited announced today that its wholly-owned subsidiary, Strides Alathur Private Limited, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility in Alathur, Chennai.
The EIR confirms the successful conclusion of a Good Manufacturing Practices (GMP) inspection conducted from April 1–5, 2024.
The shares of Strides Pharma Science Limited were trading at ₹1,298.15 down by ₹14.70 or (1.12 per cent) on NSE at 11:55 am on Monday.
The USFDA classified the inspection outcome as “Voluntary Action Indicated” (VAI). This facility, which produces tablets and capsules for the U.S. and other regulated markets, is crucial for Strides’ current and future product offerings in the United States.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.